NKGN VS AZN Stock Comparison

Performance

NKGN
10/100

NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

AZN
100/100

AZN returned 6.03% in the last 12 months. Based on SPY's performance of -21.20%, its performance is above average giving it a score of 100 of 100.

Volatility

NKGN
10/100

NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.

AZN
48/100

AZN has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Analyst Price Targets

NKGN

"Analyst Price Targets" not found for NKGN

AZN
85/100

5 analysts offer 12-month price targets for AZN. Together, they have an average target of 80.5, the most optimistic target put AZN at 82 within 12-months and the most pessimistic has AZN at 79.

Sentiment

NKGN

"Sentiment" not found for NKGN

AZN
70/100

AZN had a bullish sentiment score of 70.02% across Twitter and StockTwits over the last 12 months. It had an average of 101.58 posts, 140.17 comments, and 324.32 likes per day.

Technicals

NKGN

"Technicals" not found for NKGN

AZN
11/100

AZN receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

NKGN

"Earnings" not found for NKGN

AZN
56/100

AZN has missed earnings 3 times in the last 20 quarters.

Profit

NKGN

"Profit" not found for NKGN

AZN
77/100

Out of the last 20 quarters, AZN has had 18 profitable quarters and has increased their profits year over year on 9 of them.

All score calculations are broken down here to help you make more informed investing decisions

NKGen Biotech, Inc. Common Stock Summary

Nasdaq / NKGN

Healthcare

Biotechnology

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.

AstraZeneca PLC Summary

Nasdaq / AZN

Healthcare

Drug Manufacturers - General

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Power up your portfolio